FDA Grants Orphan Drug Designation To Annamycin For Soft Tissue Sarcoma .

 

The FDA granted orphan drug designation to annamycin for the treatment of patients with soft tissue sarcoma, according to a manufacturer-issued press release.

Annamycin (Moleculin Biotech) is a next-generation liposome-formulated anthracycline designed to eliminate cardiotoxicity and avoid multidrug resistance mechanisms associated with other approved anthracyclines. ...